

ALL IMAGES VIDEOS

57,500 Results Any time ▾

(PDF) Effective treatment of pulmonary adenocarcinoma ...<https://www.researchgate.net/publication/327472854...>

Herein, we present a case of therapeutic efficacy of osimertinib and dabrafenib plus trametinib on a 63-year-old man with advanced lung adenocarcinoma. This patient reached a remarkable ...

Effective Treatment of Lung Adenocarcinoma Harboring EGFR ...<https://www.sciencedirect.com/science/article/pii/S1556086420303282>

Aug 01, 2020 · **Methods.** In this retrospective cohort study, 15 patients with advanced lung adenocarcinoma and EGFR-activating mutation, T790M, and cis-C797S after osimertinib progression were identified by targeted next-generation sequencing. Five of these patients received a combined therapy of brigatinib and cetuximab, and 10 patients received cisplatin-based doublet chemotherapy.

Cited by: 2

Author: Yubo Wang, Nong Yang, Yongchang Zhang,...

Publish Year: 2020

(PDF) The effectiveness of afatinib and osimertinib in a ...<https://www.researchgate.net/publication/326948867...>

The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review

Search Tools

Turn off Hover Translation (关闭翻译)

ALL IMAGES VIDEOS

Add the Olive with Bing extension >

38,700 Results Any time ▾

Effective Treatment of Lung Adenocarcinoma Harboring EGFR ...<https://www.sciencedirect.com/science/article/pii/S1556086420303282>

Aug 01, 2020 Methods. In this retrospective cohort study, 15 patients with advanced lung adenocarcinoma and EGFR-activating mutation, T790M, and cis-C797S after osimertinib progression were identified by targeted next-generation sequencing. Five of these patients received a combined therapy of brigatinib and cetuximab, and 10 patients received cisplatin-based doublet chemotherapy.

Cited by: 2 Author: Yubo Wang, Nong Yang, Yongchang Zhang...
Publish Year: 2020

A case of osimertinib-resistant lung adenocarcinoma ...<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312808>

Abstract We report a case of initial lung adenocarcinoma in which transformation to small cell lung carcinoma (SCLC) was observed after acquired resistance to the 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and alternating treatment between chemotherapy and osimertinib was effective.

Cited by: 1 Author: Haruki Hirakawa, Kazutoshi Komiya, Chiho...
Publish Year: 2018

EGFR-Mutated Lung Cancers Resistant to Osimertinib through ...<https://pubmed.ncbi.nlm.nih.gov/31377341>

In addition, we retrospectively probed a case of EGFR SM lung adenocarcinoma treated with first-line osimertinib, followed by second-line erlotinib in the setting of EGFR SM/C797S. Results: Use of N-ethyl-N-nitrosourea mutagenesis against the background of EGFR L858R/C797S in conjunction with administration of gefitinib revealed preferential...

Cited by: 8 Author: Deepa Rangasathi, Ciric To, Jason E. Shipits...
Publish Year: 2019

[Full text] Durable Clinical Response of Advanced Lung ...<https://www.dovepress.com/durable-clinical...>

Herein, we present a case of therapeutic efficacy of osimertinib and dabrafenib plus trametinib on a 63-year-old man with advanced lung adenocarcinoma. This patient reached a remarkable progression-free survival of 9 months without any serious adverse reaction. At the progression of the disease, C797S mutation in cis was detected by liquid biopsy.

Author: Honggang Ding, Zhenjie Zhuang, Jingyi... Publish Year: 2020

Case Report: Lung Adenocarcinoma Harboring EGFR-19del ...<https://www.researchgate.net/publication/330794585...>

Case Report: Lung Adenocarcinoma Harboring EGFR-19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy... of 9 months in an advanced lung...

Triple Trouble: A Case of Multiple Resistance Mechanisms ...<https://europepmc.org/articles/PMC6738260>

May 01, 2019 We report a case of a patient with EGFR-mutated lung adenocarcinoma who developed a complex resistance profile: T790M mutation, HER2 mutation and HER2 amplification after first-line EGFR-TKI. This patient was safely treated with a combination of osimertinib and trastuzumab and achieved a clinically meaningful and clear molecular response.

A case of osimertinib-resistant lung adenocarcinoma ...<atm.amegroups.com/article/view/22647/21997>

Email: sueokan@cc.saga-u.ac.jp. Abstract: We report a case of initial lung adenocarcinoma in which transformation to small cell lung carcinoma (SCLC) was observed after acquired resistance to the 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and alternating treatment between chemotherapy and osimertinib was effective.

Response to tyrosine kinase inhibitors in lung ...<https://onlinelibrary.wiley.com/doi/full/10.1111/1759-7714.13606>

Osimertinib is a mutant-selective TKI approved for the treatment of T790M-positive NSCLC and has significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M-positive advanced NSCLC. A case report by Oztan et al. reported the emergence of the EGFR G724S mutation in EGFR mutant lung adenocarcinoma post...

Case Report: Osimertinib achieved remarkable and sustained ...<https://www.sciencedirect.com/science/article/pii/S0169500218303337>


Jul 01, 2018 Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex. Author links open overlay panel Mingfei Yang a 1 Xiaoling Tong b 1 Xiang Xu a Enkui Zheng a Junjun Ni a Junfang Li a Junrong Yan c Yang W. Shao b d Guofang Zhao a

1 2 3 4 5 >

13-Jan-2021 08:05PM

2284 words • 42 matches • 19 sources

FAQ



61429_Auto_EditedC.docx

Quotes Included
Bibliography Included

21%
SIMILAR

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 61429

Manuscript Type: CASE REPORT

Triple osimertinib administrations followed by chemotherapy for advanced lung adenocarcinoma : A case report

Hu XY *et al.* Successful retreatments with osimertinib for NSCLC

Xu-Yan Hu, Yu-Cheng Fei, Wen-Chao Zhou, Jin-Miao Zhu, Dong-Lai Lv

Abstract

BACKGROUND

Osimertinib is the recommended first-line treatment for adult patients with epidermal growth factor receptor (EGFR) mutation positive advanced or metastatic non-small cell lung cancer (NSCLC). However, primary or acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) seems inevitable, and when drug-resistance occurs

Match Overview

1

Internet 110 words
crawled on 03-Nov-2020
www.sagepub.com

5%

2

Internet 69 words
crawled on 15-Jun-2020
www.science.gov

3%

3

Internet 69 words
crawled on 09-Nov-2018
woc2016.elsevier.org

2%

4

Crossref 39 words
Hiroshi Yoshida, Masahiro Ooi, Young Hae Kim. "Successful Treatment with Osimertinib and Chemotherapy in a N

2%

5

Internet 29 words
crawled on 07-Jul-2019
lessera.spandidos-publications.com

1%

6

Crossref 22 words
Yong Gang, Yi-Long Wu, Le-Jie Cao, Jian-Hua Chen, Zhi-Yong Ma, Jiu-Wei Cui, Jie Wang, Hong-Bing Liu, Jing-Yan

1%

7

Internet 20 words
crawled on 01-Aug-2020
worldscientific.org


1%


8


Internet 19 words
crawled on 23-Aug-2020
www.clinicaltrials.gov


1%

PAGE: 1 OF 9









A case of osimertinib-resistant lung adenocarcinoma ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312808>

Abstract We report a case of initial lung adenocarcinoma in which transformation to small cell lung carcinoma (SCLC) was observed after acquired resistance to the 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and alternating treatment between chemotherapy and osimertinib was effective.

Cited by: 2

Author: Haruki Hirakawa, Kazutoshi Komiya, Chi...

Publish Year: 2018

Osimertinib Administration as the Primary Epidermal Growth ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859403>

Oct 15, 2019 · We herein report a case of brain metastasis of lung carcinoma that was successfully managed with osimertinib administration. Case Report A 69-year-old woman underwent chemoradiotherapy (cisplatin + docetaxel + 60Gy radiation) prior to surgery for left upper lobe lung adenocarcinoma, followed by left upper lobe resection in November 2017.

Cited by: 1

Author: Susumu Noguchi, Hiroaki Kawachi, Akari...

Publish Year: 2019

Effective Treatment of Lung Adenocarcinoma Harboring ...

<https://www.sciencedirect.com/science/article/pii/S1556086420303282>

Aug 01, 2020 · Methods. In this retrospective cohort study, 15 patients with advanced lung adenocarcinoma and EGFR-activating mutation, T790M, and cis-C797S after osimertinib progression were identified by targeted next-generation sequencing. Five of these patients received a combined therapy of brigatinib and cetuximab, and 10 patients received cisplatin-based doublet chemotherapy.

Cited by: 2

Author: Yubo Wang, Nong Yang, Yongchang Zha...

Publish Year: 2020

Triple Trouble: A Case of Multiple Resistance Mechanisms ...

<https://europepmc.org/articles/PMC6738260> ▼

May 01, 2019 · We report a case of a patient with EGFR-mutated lung adenocarcinoma who developed a complex resistance profile: T790M mutation, HER2 mutation and HER2 amplification after first-line EGFR-TKI. This patient was safely treated with a combination of osimertinib and trastuzumab and achieved a clinically meaningful and clear molecular response.

Cited by: 2

Author: Mike Ralki, Briqitte Maes, Karin Pat, Jok...